(4-nitro-benzoyl)-urea | 51884-03-8

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: (4-nitro-benzoyl)-urea
• 英文别名: (4-Nitro-benzoyl)-harnstoff；N-(aminocarbonyl)-4-nitro-benzamide；4-nitrobenzoylurea；p-Nitro-benzoyl-harnstoff；4-Nitrobenzoyl urea；N-carbamoyl-4-nitrobenzamide
• CAS: 51884-03-8
• 化学式: C₈H₇N₃O₄
• 分子量: 209.161
• InChiKey: CWHBLZNYVYKDRR-UHFFFAOYSA-N

物化性质

• 熔点：
  243-245 °C(Solv: acetic acid (64-19-7))
• 密度：
  1.468±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  0.9
• 重原子数：
  15
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  118
• 氢给体数：
  2
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  (4-nitro-benzoyl)-urea 在 溶剂黄146 、 铂 作用下， 生成 (4-amino-benzoyl)-urea
  参考文献：
  名称：

  Risk-resistance adaptation model for caregivers and their children with sickle cell syndromes

  摘要：

  This investigation examined the risk-resistance adaptation model for children with sickle cell disease and their primary caregivers. Participants were 55 children, ranging in age from 5 to 16 years with a mean age of 9 years 2 months, diagnosed with sickle cell disease and their primary caregivers, recruited from a university medical center Measures included adjustment (i.e. primary caregiver and child adjustment), risk factors (i.e. disease and disability, functional independence, and psychosocial stressors), resistance factors (i.e, intrapersonal health locus of control, social-ecological), and stress processing (coping). Primary caregivers' adjustment was associated with developmental coping, R-change(2) = .08, and child adaptation was associated with an internal health locus of control, R-change(2) = .22. An indirect effect of primary caregivers' coping on child adjustment was found through influence on primary caregivers' adjustment, R-change(2) = .11. The findings support research among other chronically ill populations that suggests an association between coping and disease adjustment. The results were interpreted to support the use of theoretically driven models in predicting the adaptation of children with chronic illness and adjustment in their caregivers.

  DOI：

  10.1007/bf02895780
• 作为产物：
  描述：

  N-(3,5-dimethylpyrazole-1-carboximidoyl)-4-nitrobenzamide 在 盐酸 作用下， 以 乙醇 为溶剂， 生成 (4-nitro-benzoyl)-urea
  参考文献：
  名称：

  Hegarty,A.F. et al., Journal of the Chemical Society. Perkin transactions II, 1973, p. 2054 - 2060

  摘要：

  DOI：

文献信息

• INDOLIN-2-ONE DERIVATIVES AS PROTEIN KINASE INHIBITORS
  申请人：ANNJI PHARMACEUTICAL CO., LTD.

  公开号：US20130281451A1

  公开（公告）日：2013-10-24

  A novel class of indoline-2-one derivatives are disclosed. These compounds are protein kinase inhibitors which are useful for treating hyperproliferative diseases such as cancer.

  揭示了一类新型的吲哚啉-2-酮衍生物。这些化合物是蛋白激酶抑制剂，可用于治疗癌症等过度增殖性疾病。
• Piperidyl - urea, - thiourea and - guanidine derivatives, and intermediates therefor, processes for preparing them and pharmaceutical compositions containing the derivatives
  申请人：JOHN WYETH & BROTHER LIMITED

  公开号：EP0035374A2

  公开（公告）日：1981-09-09

  The invention concerns psychotropic agents useful as antidepressants having the formula and acid addition and quaternary ammonium salts thereof, wherein the dotted line represents an optional bond, Ar represents a ring system of formula in which Q is O,S,-CR7=CR8- and -N=N-; R4, R5 and R6, and R7 and R8 when present, each represent hydrogen or defined substituents and additionally either R4 and R5 when adjacent or R6 and R8 when adjacent, together with the carbon atoms to which they are attached also represent a fused five or six membered carbocyclic or heterocyclic ring optionally carrying one or more defined substituents; R is an optionally substituted aryl or heteroaryl radical or a cycloalkyl radical containing 5 to 7 carbon atoms; R1, R2, R3 and R9 are each hydrogen or a lower alkyl group; n is 0 or 1; X is =0, =S or =NH; Y is -O- or a direct bond and Z is -CO- or -CH2- with the proviso that when Ar is unsubstituted phenyl and R9 is hydrogen then Y is -0-. Processes for preparing the compounds and pharmaceutical compositions containing them are also disclosed. Analogues having a pyridinium ring or ZR representing hydrogen are also disclosed as intermediates.

  本发明涉及可用作抗抑郁剂的精神药物，其化学式为 及其酸加成盐和季铵盐，其中虚线代表任选键，Ar 代表式 其中 Q 是 O、S、-CR7=CR8- 和 -N=N-；R4、R5 和 R6 以及 R7 和 R8（当存在时）各自代表氢或定义的取代基，此外，R4 和 R5（当相邻时）或 R6 和 R8（当相邻时）与它们所连接的碳原子一起还代表可选带一个或多个定义取代基的融合的五或六成员碳环或杂环；R是任选取代的芳基或杂芳基或含有5至7个碳原子的环烷基；R1、R2、R3和R9各自是氢或低级烷基；n是0或1；X是＝0、＝S或＝NH；Y是-O-或直接键，Z是-CO-或-CH2-，但当Ar是未取代的苯基且R9是氢时，则Y是-0-。 此外，还公开了制备这些化合物和含有这些化合物的药物组合物的工艺。还公开了具有吡啶鎓环或 ZR 代表氢的类似物作为中间体。
• Jacobs; Heidelberger, Journal of the American Chemical Society, 1917, vol. 39, p. 2437
  作者：Jacobs、Heidelberger

  DOI：——

  日期：——
• 83. Some symmetrical acylarylureas
  作者：Edward N. Abrahart

  DOI：10.1039/jr9380000424

  日期：——
• Prabhakaran, P V; S, Jayadev; Nema, S K, Indian Journal of Chemistry - Section B Organic and Medicinal Chemistry, 1991, vol. 30, # 11, p. 1072 - 1073
  作者：Prabhakaran, P V、S, Jayadev、Nema, S K、Rao, K V C

  DOI：——

  日期：——

表征谱图